Patient has an unresolved ? Grade adverse event (AE) from a previous antineoplastic treatment, excluding alopecia and phlebitis Unresolved acute toxicity from prior anticancer therapy Unresolved toxicity from prior chemotherapy (subjects must be recovered to ? Grade toxicity from previous anticancer treatments or previous investigational products. Unresolved chronic toxicity > grade from prior therapy Unresolved toxicity higher than CTCAE (v. .) Grade attributed to any prior therapy/procedure excluding alopecia and hypothyroidism; Unresolved toxicity higher than CTCAE grade attributed to any prior therapy/procedure excluding alopecia Unresolved CTCAE >Grade toxicity (other than stable toxicity) from previous anti-cancer therapy excluding alopecia. Have any unresolved chronic toxicity with CTC AE grade >= , from previous anti-NF therapy, except for alopecia Unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment Patients with unresolved > Grade toxicity associated with any prior antineoplastic therapy Has unresolved toxicities from previous anticancer therapy Patients with unresolved > Grade toxicity associated with any prior antineoplastic therapy Persistent, unresolved ?Grade clinically significant drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy) associated with previous treatment Any unresolved toxicity (>= CTCAE grade ) from previous anti-cancer therapy, excluding alopecia Any unresolved >= grade pulmonary toxicity from previous anti-cancer therapy Any unresolved grade or higher toxicity from previous anti-cancer therapy Unresolved grade or greater toxicity from most recent treatment, including chemotherapy, hormonal therapy, or radiotherapy, at the time of study enrollment Unresolved toxicity higher than NCI-CTCAE version . grade attributed to any prior therapy/procedure excluding anemia or neuropathy grade and alopecia of any grade Have any unresolved chronic toxicity with CTCAE grade >= , from previous anti-NF therapy, except for alopecia Unresolved toxicity higher than CTCAE grade attributed to any prior therapy/procedure excluding alopecia Unresolved toxicity from previous anticancer therapy or incomplete recovery from surgery Any unresolved toxicity > CTCAE grade despite optimal care/support, from previous anti-cancer therapy, except for alopecia, within days prior to Cycle , day Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment Any unresolved toxicity ? Grade from previous anticancer therapy except for stable chronic toxicities (? Grade ) not expected to resolve. Patients with unresolved > Grade toxicity associated with any prior antineoplastic therapy Unresolved toxicities from previous anticancer therapy. Unresolved > Grade toxicity associated with any prior antineoplastic therapy Unresolved toxicity higher than CTCAE grade attributed to any prior therapy/procedure, excluding alopecia Subjects experiencing unresolved toxicity of previous antitumor therapy which is CTCAE grade > before the start of study treatment, except for alopecia or hemoglobin >= . g/dL or >= . mmol/L Any unresolved toxicity ? Grade (except stable Grade peripheral neuropathy or alopecia) from previous anticancer therapy Subject has any unresolved toxicity Grade > from previous anti-cancer therapy Unresolved toxicities from prior anticancer therapy Has unresolved toxicity of greater than or equal to CTCAE Grade attributed to any prior therapies. Unresolved toxicities from previous anticancer therapy Any unresolved toxicity greater than Common Toxicity Criteria (CTC) grade from previous anti-cancer therapy Adverse effects due to prior therapy unresolved at randomization Any unresolved toxicity > Common Toxicity Criteria Grade (except alopecia) from previous anticancer therapy (including radiotherapy) Any unresolved toxicity NCI CTCAE Grade ? from previous anticancer therapy Unresolved toxicities from prior therapy Unresolved toxicity greater than CTCAE (version .) grade attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity =< grade Any unresolved toxicity NCI CTCAE Grade ? from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criterion; Significant unresolved toxicities from previous anticancer therapy that have not resolved, or have not stabilized at a new baseline Unresolved toxicities from prior anticancer therapy Any unresolved toxicity NCI CTCAE Grade ? from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criterion Any unresolved toxicity CTCAE >Grade from the prior chemoradiation therapy. Unresolved toxicity higher attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin- induced neurotoxicity ? Grade for at least days; Any unresolved toxicity CTCAE >Grade from previous anti-cancer therapy. Unresolved toxicity from other agents. Patients with unresolved Common Terminology Criteria for Adverse Events (CTCAE) version (v). grade or greater toxicity from prior administration of another investigational drug and/or anti-cancer treatment are not eligible. Unresolved toxicity higher than CTCAE v. . grade attributed to any prior therapy/procedure excluding alopecia and oxaliplatin-induced neurotoxicity (which must be =< grade ) Any unresolved toxicity greater or equal to grade from previous anticancer therapy, except for stable chronic toxicities not expected to resolve Patients with any unresolved toxicity greater than Grade from previous anticancer therapy Unresolved toxicity higher than CTCAE v. . grade attributed to any prior therapy/procedure excluding alopecia and oxaliplatin-induced neurotoxicity (which must be =< grade ) Any unresolved toxicity (> CTCAE grade ) from previous anti-cancer therapy Has any unresolved toxicity ? Grade from previous anticancer therapy Subjects experiencing unresolved toxicity of previous antitumor therapy (excluding alopecia) which is CTCAE Grade > at screening Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities greater than grade ) Any unresolved chronic toxicity greater then Common Terminology Criteria (CTC) grade from previous anticancer therapy Unresolved toxicities from prior anticancer therapy. Patient with an unresolved ? Grade AE from a previous antineoplastic treatment, excluding alopecia. Patient has an unresolved ? Grade AE from a previous antineoplastic treatment, excluding alopecia. Unresolved clinically significant toxicity greater than Grade from previous anti-cancer therapy Has unresolved toxicity of greater than or equal to CTCAE Grade attributed to any prior therapies Unresolved toxicity higher than NCI-CTCAE version . Grade attributed to any prior therapy/procedure (excluding alopecia or anemia or grade neuropathy that is not reversible due to oxaliplatin) Any unresolved >=Grade (per CTCAE v .) toxicity from previous anti-cancer therapy at the time of enrollment, except alopecia or Grade anemia (if hemoglobin is >. g/dL) Unresolved, clinically significant toxicity from prior therapy, except for alopecia and Grade peripheral neuropathy Grade or greater unresolved toxicity from prior antineoplastic therapy Any unresolved toxicity greater than CTCAE grade (except alopecia, and certain other unresolved CTCAE grade toxicities including bone marrow hypocellularity, lymphopenia, infusion-related reaction, infusion site extravasation, injection site reaction, portal vein hypertension, obesity) from previous anti-cancer therapy; patients with grade neuropathy will be evaluated on a case by case basis for entry into study; pre-chemotherapy medical conditions will be taken into consideration Patient experiencing unresolved toxicity ? CTCAE grade (except alopecia) from previous agents. Any unresolved chronic toxicity greater than CTC grade from previous anticancer therapy (except alopecia) Unresolved toxicities from prior therapy Unresolved toxicity from other agents; participants with unresolved or unstable Common Toxicity Criteria Adverse Event version (CTCAE v) grade or greater toxicity from prior administration of another anti-cancer treatment are not eligible Unresolved chronic toxicity of previous AML treatment Has unresolved toxicities from previous anticancer therapy Unresolved specific chronic toxicity of previous treatment of grade > except for alopecia or hemoglobin ?. g/dL (or ?. mmol/L)